<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01851603</url>
  </required_header>
  <id_info>
    <org_study_id>12-1186</org_study_id>
    <secondary_id>1U01MH094247</secondary_id>
    <nct_id>NCT01851603</nct_id>
  </id_info>
  <brief_title>Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects</brief_title>
  <acronym>AVL3288</acronym>
  <official_title>Phase I, Single-center, Inpatient, Randomized, Double-blind, Placebo-controlled, Dose Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profiles of Single Oral Doses of AVL-3288 (Anvylic-3288) Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a brief inpatient study to determine the safety of a new drug in healthy people.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AVL-3288, a &quot;first in class&quot; small molecule, selective allosteric modulator of the α7 nAChR,
      is implicated in the cognitive deficit in patients with neurologic and psychiatric disorders,
      including schizophrenia, Alzheimer's disease and attention deficit hyperactivity disorder.
      The mechanism of action, the allosteric modulation of α7 nAChR and improvement of cognitive
      and memory function both in relevant animal models and patients has been clearly described in
      recent literature. The effect of AVL-3288 strongly supports the rationale for use in
      schizophrenia given the dose effect relationship, peaking at a low dose in rats (HED 3 mg),
      in rodent schizophrenia and memory models. Phase I, single-center, inpatient, randomized,
      double-blind, placebo-controlled, dose escalating study to evaluate the safety, tolerability
      and pharmacokinetic profiles of single oral doses of AVL-3288 in healthy subjects. Subjects
      will be hospitalized in the University of Colorado Clinical Research Center (CTSA) for a 12
      hour period after the single dose. Then there will be an ambulatory 24 and 48 hour
      observation and washout period of 10. Patients will receive an evoked potential measurement,
      the P50 sensory gating paradigm, and the Repeatable Battery for Assessment of
      Neuropsychological Status.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left institution
  </why_stopped>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>48 hours</time_frame>
    <description>0,1,2,3, 4, 6, 8 ,12, 24, 48 hours post dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events.</measure>
    <time_frame>10 days</time_frame>
    <description>Corrected QT interval &gt; 500 ms; hepatic enzyme &gt; 3 times above the upper limit of normal values; systolic blood pressure &gt; 200 mm Hg or diastolic blood pressure &lt; 50 mm Hg.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Repeatable Battery for Assessment of Neuropsychological Status Total Scale T Score</measure>
    <time_frame>24 hours</time_frame>
    <description>T score on Total Scale of the Repeatable Battery for Assessment of Neuropsychological Status, differences between AVL-3288 or placebo arms and pretreatment baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>P50 Auditory Sensory Gating Ratio</measure>
    <time_frame>24 hours</time_frame>
    <description>Ratio = (Conditioning P50 amplitude-Test P50 Amplitude)/Conditioning P50 Amplitude, differences between AVL-3288 or placebo arms from baseline.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>AVL-3288</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of AVL-3288</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AVL-3288</intervention_name>
    <description>Drug</description>
    <arm_group_label>AVL-3288</arm_group_label>
    <other_name>UCI-4083</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical diluent to that used for AVL-3288</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>Diluent solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteer

        Exclusion Criteria:

          -  Substance use. We do not accept inquiries by email.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Freedman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>U of Colorado Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ng HJ, Whittemore ER, Tran MB, Hogenkamp DJ, Broide RS, Johnstone TB, Zheng L, Stevens KE, Gee KW. Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc Natl Acad Sci U S A. 2007 May 8;104(19):8059-64. Epub 2007 Apr 30.</citation>
    <PMID>17470817</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2013</study_first_submitted>
  <study_first_submitted_qc>May 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2013</study_first_posted>
  <last_update_submitted>December 28, 2016</last_update_submitted>
  <last_update_submitted_qc>December 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

